Arca
Skip to content
Tools
Tools

Interleukin-2 receptor

Complex in Homo sapiens that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 4
  • In phases 1 to 3: 0
  • Sponsors: 3
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on IL2RA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2
  • Protein or peptide 2

Approved4

  • Aldesleukin
  • Basiliximab
  • Denileukin diftitox
  • Daclizumab

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        • Beijing VDJBio Co., LTD.125%

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        AldesleukinBoxed warningApprovedNovartis PharmaceuticalsProtein or peptideAgonistInterleukin-2 receptor agonist64
        BasiliximabBoxed warningApprovedNovartis PharmaceuticalsAntibodyInhibitorInterleukin-2 receptor inhibitor13
        Denileukin diftitoxBoxed warningApprovedBeijing VDJBio Co., LTD.Protein or peptideBinding agentInterleukin-2 receptor binding agent4
        DaclizumabWithdrawnApprovedBiogenAntibodyInhibitorInterleukin-2 receptor inhibitor2

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov.
        Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisAldesleukin, Denileukin diftitoxPhase 1RecruitingBeijing VDJBio Co., LTD.Nov 12, 2026
        Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerAldesleukinPhase 2Not yet recruitingBeth Israel Deaconess Medical CenterNov 9, 2026
        A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaAldesleukinPhase 2RecruitingIovance Biotherapeutics, Inc.Aug 3, 2026
        Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCTDaclizumabPhase 3RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyJul 8, 2026
        A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaAldesleukinPhase 1 / Phase 2RecruitingAstraZenecaJul 2, 2026
        A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic MelanomaAldesleukinPhase 2Not yet recruitingEast Metropolitan Health Service, AustraliaJun 16, 2026
        Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseAldesleukinPhase 1 / Phase 2RecruitingThe Methodist Hospital Research InstituteJun 16, 2026
        Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal TumorsAldesleukinPhase 2Not yet recruitingJoal BeaneJun 15, 2026
        Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T CellsAldesleukinNot applicableRecruitingCambridge University Hospitals NHS Foundation TrustMay 28, 2026
        Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationBasiliximabPhase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMay 7, 2026
        Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's DiseaseBasiliximabPhase 1RecruitingRoyan InstituteMay 7, 2026
        Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AMLBasiliximab—Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMay 7, 2026
        Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant RecipientsBasiliximabPhase 4Active, not recruitingUniversity of GuadalajaraFeb 24, 2026
        Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALLBasiliximabPhase 2 / Phase 3RecruitingShanxi Bethune HospitalJul 10, 2025
        HCW9302 (Interleukin-2 Fusion Protein) for Alopecia AreataDenileukin diftitoxPhase 1RecruitingHCW BiologicsJul 3, 2025
        A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelDenileukin diftitoxPhase 1 / Phase 2RecruitingIovance Biotherapeutics, Inc.Apr 23, 2025
        Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic DiseasesBasiliximabPhase 2Not yet recruitingAnhui Provincial HospitalJun 28, 2024
        1 vs 7 RATG Infusions in Renal TransplantationBasiliximab—Active, not recruitingMario Negri Institute for Pharmacological ResearchApr 18, 2024
        Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDiesBasiliximabPhase 3RecruitingUniversity Hospital, ToursMay 23, 2022
        T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsDenileukin diftitoxPhase 1 / Phase 2Active, not recruitingAlexander B Olawaiye, MDJan 20, 2022
        Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive RegimenDaclizumabPhase 1Active, not recruitingCity of Hope Medical CenterJun 27, 2008

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364167, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.